Search results: (10000)
News Myths Accompanying Therapy of Arterial Hypertension
Arterial hypertension is among the most common yet most underestimated diseases in the adult population. Misinterpretation of data and inadequate management of this disease can be caused, among other things, by an excessive amount of available clinical data and its incorrect analysis. Insufficient control of blood pressure (BP) is, however, one of the most significant factors in increased cardiovascular (CV) mortality.
News Efficacy and Safety of Etanercept in the Therapy of Arthritis
A review by experts from Genoa, Italy, focused on the available knowledge regarding the efficacy and safety of etanercept in the treatment of inflammatory rheumatic diseases.
News Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?
Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the immunosuppressant cyclosporine A does not have sufficient efficacy in some patients with AD or is contraindicated for them. Therefore, the phase III clinical trial LIBERTY AD CAFÉ evaluated the efficacy of dupilumab in these patients.
News Fixed Combination of Trastuzumab and Pertuzumab for Subcutaneous Administration in Patients with Early Breast Cancer
At a symposium focused on breast cancer, held in December 2019 in San Antonio, Texas, preliminary results of the FeDeriCa clinical study were presented – comparing the pharmacokinetics, efficacy, and safety of a fixed combination of trastuzumab and pertuzumab for subcutaneous administration versus intravenous administration in patients with early-stage HER2-positive breast cancer. Based on the presented results, the drug received approval from the U.S. Food and Drug Administration (FDA).
News Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results of this study 5 years after initiation.
News Summary of New American Recommendations for Heart Failure Management
This year, the American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA) released joint recommendations for the diagnosis and treatment of heart failure in clinical practice. These new guidelines replace the previous recommendations from 2013 and their 2017 update. We summarize the 10 key points to remember as outlined by the authors of the new guidelines and focus on the treatment of the subgroup of patients with heart failure with preserved ejection fraction (HFpEF).
News ADCT – a simple tool for self-diagnosis of patients with severe atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory disease not only of childhood. It can negatively affect the quality of life despite being treatable. Control and management of the disease in different areas of life can be easily evaluated using the ADCT questionnaire.
News Management of Adverse Effects During Maintenance Treatment of AML Patients
The randomized phase III study QUAZAR AML-001 evaluated the maintenance treatment of acute myeloid leukemia (AML) in patients after first remission. The following text summarizes the findings regarding the most common adverse events (AEs) in this therapy and practical recommendations for managing side effects based on guidelines from professional societies.
News Emicizumab Changes the Lifestyle of Patients with Hemophilia A
At the World Federation of Hemophilia (WFH) meeting, data were presented regarding the impact of emicizumab on the lifestyle of people with hemophilia A.
News Efficacy and Safety of Romosozumab in Postmenopausal Women with Osteoporosis and Renal Impairment
The coexistence of osteoporosis and chronic kidney disease (CKD) increases the risk of fractures and overall mortality in patients. A recent post-hoc analysis of two controlled randomized multicenter studies (FRAME and ARCH) investigated the efficacy and safety of romosozumab in postmenopausal women with osteoporosis and mild to moderate CKD.
News Cost-effectiveness in Bleeding Control for Acquired Hemophilia A
A pharmacoeconomic analysis showed favorable cost-effectiveness of activated prothrombin complex concentrate in the indication of bleeding control in patients with acquired hemophilia A.
News Final Analysis of the STASEY Study: How Did Emicizumab Perform in Prophylaxis of Hemophilia A Patients with FVIII Inhibitors?
The July virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021 offered a range of interesting topics. In its poster section, data from the multicenter single-arm open-label phase III clinical trial STASEY, which evaluated the safety and tolerance of emicizumab prophylaxis in patients with hemophilia A and an inhibitor of coagulation factor VIII (FVIII), were presented. Víctor Jiménez-Yuste from La Paz University Hospital in Madrid presented the study results on behalf of the international team of authors.
News Impact of Empagliflozin on the Risk of Cardiovascular Death and Need for Hospitalization Due to Heart Failure
In the EMPA-REG OUTCOME study, empagliflozin reduced the risk of cardiovascular death and the number of hospitalizations due to heart failure in patients with type 2 diabetes (T2DM) who had confirmed cardiovascular disease at study entry. In the following analysis, the authors focused on the benefit of empagliflozin in patients with different levels of risk for heart failure development.
News High Dose of Protein Affects Mortality in Critically Ill Patients if They Do Not Have Sepsis
The optimal composition of nutrition in terms of adequate energy and protein intake for critically ill patients is still a subject of professional discussion. The study cited below aimed to shed more light on this issue by evaluating how early intake of high amounts of proteins and excessive energy intake affects mortality in these patients.
News Trifluridine/tipiracil, regorafenib, or supportive therapy? Factors affecting the success of mCRC treatment
Currently, there are no biomarkers available to help decide, for a specific patient with refractory metastatic colorectal cancer (mCRC), whether therapy with trifluridine/tipiracil or regorafenib will be more effective and which patients will benefit the most from the treatment. A group of Czech oncologists presented the results of their analysis on this topic at the Gastrointestinal Symposium of the American Society of Clinical Oncology (ASCO) held in January 2020 in San Francisco.
News Reflection of Progress in Hemophilia Treatment in Current WFH Recommendations
In June 2020, the new, third guidelines of the World Federation of Hemophilia (WFH) were introduced. They are based on the fact that in the past 5 years there has been significant progress in the management of hemophilia, mainly due to the introduction of new − even revolutionary − drugs into clinical practice.
News Aclidinium bromide improves the quality of life for COPD patients
The ON-AIR study conducted in real practice demonstrated the benefits of aclidinium bromide for the quality of life of patients with chronic obstructive pulmonary disease (COPD). It also assessed the impact of treatment on the severity of nocturnal and morning symptoms and their impact on daily activities.
News The Immune System in the Pathophysiology of ITP
From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that the etiology of this disease is very complex and involves both antibody and cellular immunity.
News Quality of Life of Hemophiliacs and Ways to Improve It
Determining the quality of life (QoL) also reflects the morbidity associated with the disease, in this case, hemophilia. In the study presented below, the authors focused on determining QoL in relation to socioeconomic and other characteristics.
News Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles
The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the journal Multiple Sclerosis was to evaluate the efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS) who received alemtuzumab in additional cycles beyond the first 2 cycles.
News Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation factor VIII (FVIII) concentrate. Recently, some hemophiliacs have also been switched to prophylaxis with so-called non-factor therapy, specifically emicizumab. A recently published report from the USA shows a comparison of these two modalities in real clinical practice.
News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?
The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?